Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bausch + Lomb Corporation (BLCO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, drawn directly from the EDGAR system. As a Canadian-incorporated issuer with common shares listed on the New York Stock Exchange and the Toronto Stock Exchange, Bausch + Lomb files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits such as credit agreements, indentures and press releases.
For an eye health company operating in vision care, surgical products and ophthalmic pharmaceuticals, these filings contain detailed information on segment performance, risk factors, capital structure and governance. Recent Form 8-K filings describe material events including secured notes offerings, amendments to the company’s credit and guaranty agreement, creation of new term loan tranches and revolving credit facilities, refinancing of existing borrowings, quarterly financial results, investor day materials and changes in the composition of the board of directors.
Investors can use this page to review Bausch + Lomb’s disclosures on direct financial obligations, covenants, leverage ratios and maturity profiles, as well as governance items such as director appointments, committee assignments and executive compensation arrangements referenced in current reports. Over time, the archive will also include annual 10-K reports and quarterly 10-Q reports, which provide more comprehensive discussions of the company’s business, segments, risk factors and financial statements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the nature of new term loans, secured notes, amendments, results of operations and other reported events. Users can also monitor current reports that reference press releases on topics such as investor day presentations, refinancing transactions and quarterly earnings, using this page as a central source for BLCO’s regulatory history and ongoing disclosure record.
Bausch & Lomb Corp executive Robert D. Bailey, EVP & Chief Legal Officer, reported new activity in company stock. On March 6, 2026, he made an open-market purchase of 14,600 common shares at an average price of $17.146 per share, held in his self-directed IRAs.
In connection with this purchase, he also acquired 14,600 matching restricted share units (MRSUs) under the company’s matching share program. These MRSUs vest in three equal annual installments over three years, contingent on his continued service, bringing his direct holdings to 246,490 common shares after the reported transactions.
Bausch & Lomb Corp Executive Vice President and CFO Sam Eldessouky reported new insider activity in common shares. He made an open-market purchase of 4,000 common shares at $17.13 per share, increasing his direct ownership.
In connection with this purchase, he was also granted 4,000 matching restricted share units (MRSUs) under the company’s matching share program. One-third of these MRSUs will vest on each of the first, second, and third anniversaries of the grant date, subject to his continued service. Following these transactions, he directly holds 407,130 common shares.
Bausch & Lomb Corp CEO and Chairman Brent L. Saunders reported buying 14,700 common shares in an open-market transaction at a weighted average price of about $17.14 per share, with trade prices ranging from $17.09 to $17.19. He also received 14,700 matching restricted share units under the company’s matching share program, which vest in three equal annual installments if he continues in service. Following these transactions, he directly holds 981,275 common shares.
Bausch & Lomb Corp director Ross Thomas W. Sr. reported two transactions in common shares. He made an open-market purchase of 4,500 common shares at a weighted average price of $17.679 per share, increasing his direct holdings to 64,891 shares immediately after the trade. In connection with this purchase, he also acquired 4,500 matching restricted share units (MRSUs) under the company’s matching share program, bringing his total reported direct holdings to 69,391 shares. One-third of these MRSUs will vest on each of the first, second, and third anniversaries of the grant date, subject to his continued service, with limited exceptions.
Bausch & Lomb Corp director Alfonso Eduardo increased his stake through an open-market purchase and a related equity award. He bought 4,300 common shares at a price of $17.90 per share, bringing his directly held shares to 9,555 immediately after the purchase.
In connection with this purchase and under the company’s matching share program, he was granted 4,300 matching restricted share units, which raised his total direct holdings to 13,855 common shares. One-third of these matching restricted share units will vest on each of the first, second, and third anniversaries of the grant date, subject to his continued service, apart from limited circumstances.
Bausch & Lomb Corp director Andrew C. Von Eschenbach reported two transactions in common shares. He made an open-market purchase of 4,364 shares at $18.305 per share, increasing his direct holdings to 66,450 shares. In connection with this purchase, he also received a grant of 4,364 matching restricted share units under the company’s matching share program, which will vest in three equal installments on each of the first, second, and third anniversaries of the grant date, subject to his continued service.
Bausch & Lomb Corp senior vice president, controller and chief accounting officer Frederick Munsch reported multiple share dispositions related to tax withholding. On February 27, he disposed of 2,437 and 5,692 common shares at $18.30 per share through tax-withholding transactions. On February 26, he disposed of an additional 2,042 common shares at $18.49 per share, also for tax withholding.
According to the footnotes, these shares were withheld to cover tax obligations due upon the vesting of restricted share units and performance-based restricted share units, rather than being discretionary open-market sales.
Bausch & Lomb Corp executive Andrew J. Stewart reported tax-related share dispositions tied to vesting of restricted share units. On February 26, he had 2,984 common shares withheld at $18.49 per share to cover tax obligations, leaving 92,656 common shares owned directly afterward.
On February 27, an additional 2,007 common shares were withheld at $18.30 per share for the same purpose, leaving him with 90,649 directly owned common shares following this transaction. These Form 4 entries reflect tax-withholding dispositions rather than open-market purchases or sales.
Bausch & Lomb Corp executive Luc Bonnefoy, President of Surgical, reported tax-related dispositions of common shares tied to equity awards. On February 26, 2026, 4,404 common shares at $18.49 per share were withheld to cover tax obligations upon vesting of restricted share units, leaving 113,533 shares held directly.
On February 27, 2026, 4,311 common shares and 9,221 common shares, each at $18.30 per share, were similarly withheld to satisfy tax liabilities on vesting of restricted and performance-based restricted share units, leaving 109,222 and 100,001 common shares, respectively, held directly after these transactions.
Bausch & Lomb Corp executive Yehia Hashad reported tax-related share dispositions. On February 26–27, he had several Form 4 transactions coded "F," where common shares were withheld at prices around $18.30–$18.49 to cover tax obligations upon vesting of restricted and performance-based restricted share units. After one February 27 transaction, he held 180,041 common shares directly.